角用环球( NIVERS 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED (於香港註冊成立的有限公司) 股份代號：2666 中期報 目錄 2 公司資料 65 簡明綜合中期財務資料的審閱報告 66 簡明中期合併利潤表 4 定義 67 簡明中期合併綜合收益表 6 公司簡介 68 簡明中期合併財務狀況表 7 業績概覽 70 簡明中期合併權益變動表 9 管理層討論與分析 72 簡明中期合併現金流量表 55 權益披露 75 簡明綜合中期財務資料附註 58 企業管治 60 其他資料 公司資料 | --- | --- | --- | |-------|--------------------------------|--------------------------------| | | | | | | 董事會 | 薪酬委員會 | | | 主席及副主席 | 鄒小磊先生 （主席） | | | 彭佳虹女士 （主席） | 陳啟剛先生 | | | （副主席） | 徐明先生 | | | 陳啟剛先生 | 李引泉先生 | | | 執行董事 | 許志明先生 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 截至2023年6月30日止六個月的中期業績 | --- | --- | |-------|-------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | • | 截至 2023 年 6 月 30 日止六個月，收入約人民幣 6,634.4 百萬元，較 2022 年同期的約 人民幣 5,712.3 百萬元增長 16.1% 。 | | • | 截至 2023 年 6 月 ...

動用环球座 UNIVERSA 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED (於香港註冊成立的有限公司) 股份代號：2666 年 度 報 告 2022 93 董事會報告 125 2022年度環境、社會及管治報告 | --- | --- | --- | --- | |-------|------------------|-------|----------------| | | 目錄 | | | | 2 | 公司資料 | 189 | 獨立核數師報告 | | 4 | 定義 | 194 | 合併損益表 | | 7 | 公司簡介 | 195 | 合併綜合收益表 | | 8 | 董事會主席致辭 | 196 | 合併財務狀況表 | | 11 | 業績概覽 | 198 | 合併權益變動表 | | 13 | 管理層討論與分析 | 200 | 合併現金流量表 | | 62 | 企業管治報告 | 203 | 財務報表附註 | | 84 | 董事簡歷 | | | 公司資料 | --- | --- | --- | --- | |-------|------ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 截至2022年12月31日止年度 全年業績公告 | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | • | 截至 2022 年 12 月 31 日止年度，收入約人民幣 11,912.1 百萬元，較 2021 年的約 人民幣 9,914. ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion HKD for the first half of 2020, representing a 15% growth compared to the same period last year[1]. - Total revenue for the first half of 2020 reached RMB 4,024.2 million, a 25.9% increase compared to the same period last year[10]. - Profit for the period was RMB 861.0 million, a slight decrease of 1.3% year-on-year[10]. - The company reported a net profit margin of 12% for the first half of 2020, an improvement from 10% in the previous year[1]. - The pre-tax profit decreased by 5.5% to RMB 1,128.2 million, while the profit attributable to ordinary shareholders was RMB 793.4 million, down 2.3% year-on-year[20]. - The net profit for the first half of 2020 was RMB 860,978 thousand, slightly down from RMB 872,525 thousand in the same period of 2019, representing a decrease of 1.5%[133]. - The total comprehensive income for the first half of 2020 was RMB 879,849 thousand, slightly up from RMB 873,774 thousand in the same period of 2019[133]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2022[1]. - The company provided a positive outlook for the second half of 2020, projecting a revenue growth of 10% to 15%[1]. - New product launches are expected to contribute an additional 200 million HKD in revenue by the end of the fiscal year[1]. - The company is considering strategic acquisitions to bolster its service offerings, with a budget of up to 500 million HKD allocated for potential deals[1]. - The company plans to explore specialized operations, integration of medical and elderly care, and investments in the healthcare industry in the future[18]. Operational Efficiency and Innovations - Ongoing research and development efforts have led to the introduction of two new medical technologies, projected to enhance operational efficiency by 30%[1]. - The group has established 4 internet hospitals and has launched 13 member medical institutions on its internet platform, achieving a 5.1% conversion rate from offline to online within 4 months[17]. - The company is focusing on expanding its financing lease business into new industries to mitigate the impact of the COVID-19 pandemic on business development[27]. Financial Position and Assets - Total assets as of June 30, 2020, amounted to RMB 59,199.2 million, reflecting a 2.3% increase from the end of 2019[10]. - The return on total assets was 2.94%, down from 3.33% in the previous year[8]. - The return on equity was 16.41%, compared to 18.89% in the same period last year[8]. - The company maintained a provision coverage ratio of 199.68%[9]. - The group's total liabilities amounted to RMB 45,203.1 million, an increase of RMB 797.8 million or 1.8% compared to the end of the previous year[61]. Employee and Corporate Governance - The group employed 12,783 staff as of June 30, 2020, reflecting a 45.9% increase from 8,761 employees as of December 31, 2019[108]. - Approximately 52.3% of the group's employees hold a bachelor's degree or higher, indicating a highly educated workforce[108]. - The company has maintained a high level of corporate governance standards to protect shareholder interests and enhance corporate value[116]. - The audit committee consists of three members, including two independent non-executive directors with appropriate professional qualifications[118]. Risk Management and Credit Quality - The company has implemented a prudent risk management policy, with a focus on improving the asset classification policy to mitigate systemic risks[55]. - The company continues to enhance its risk management system and has taken effective measures to recover non-performing assets[55]. - The average expected credit loss rate for total accounts receivable was 7% as of June 30, 2020, compared to 5% as of December 31, 2019, indicating a deterioration in credit quality[193]. - The company implemented certain relief measures for customers affected by the COVID-19 pandemic, which may impact the repayment records and credit risk assessments moving forward[197]. Cash Flow and Investments - The cash flow from operating activities for the first half of 2020 was a net inflow of RMB 614.0 million, an increase of RMB 5,220.4 million compared to the same period last year[78]. - The cash flow from investing activities was a net outflow of RMB 17.3 million, a decrease of RMB 2,702.5 million compared to the same period last year[78]. - The company reported a decrease in cash dividends paid, totaling RMB (454,117) thousand compared to RMB (407,210) thousand in the previous year[140]. - The company recorded a realized loss from non-hedging derivative financial instruments of RMB (70) thousand, a significant improvement from RMB (3,450) thousand in the previous year[140]. Stock Options and Shareholder Returns - The company has adopted a stock option plan allowing for a maximum of 171,630,458 shares to be issued, which is 10% of the total issued share capital[120]. - The board decided not to declare an interim dividend for the six months ending June 30, 2020[125]. - The stock options granted are subject to a vesting period of 24 months from December 31, 2019[122].